RMT Epigenomex, Inc.

RMT Epigenomex partners with biotech and pharmaceutical companies, CROs and academia to significantly reduce the time and cost of epigenetic drug discovery.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Buffalo, NY, US
  • Currency USD
  • Founded March 2014
  • Employees 3
  • Website rmt-epigenomex.com

Company Summary

RMT Epigenomex operates in the exciting, fast growing field of epigenetics. With an estimated $8 billion market size, epigenetics offers a more targeted drug development method. RMT provides a better tool by adding significant reductions in both time and cost of development – specifically 2 to 3 years in time savings. The company’s technology is highly scalable, allowing it to influence multiple stages of the drug development process.

Team

  • Chief Operating Officer and Chief Financial Officer

    Steve has over 25 years of experience in private equity, capital markets and early-stage investing. Steve is on the Advisory Committee for Star Mountain Capital, a fund group focused on small and medium sized-companies, and has angel investments in industries including healthcare and technology. Steve holds an MBA in Finance from Fordham University & a Bachelor of Engineering degree in Electrical Engineering from Stevens Institute of Technology.

  • Joe Harris
    President and Chief Executive Officer

    Joe has over 25 years of experience in M&A and venture capital, and has a diverse background in the health industry, accounting, and law. He served in senior management positions at Glaxo SmithKline, and Eastman Kodak, where he completed over $16 Billion in M&A transactions. He previously served on the Board of Directors of PacificHealth Labs and Orthovita. He is a CPA with a JD, an MBA in Finance and a BS in Accounting from Syracuse University.

  • Chief Scientific Officer

    John was the first to demonstrate a requirement for specific protein methylation in the cellular development of neuronal model systems. As a faculty member at SUNY at Buffalo, John spent 17 yrs teaching & writing peer-reviewed research in post-translational protein modification & methylation biology. He received a doctoral degree and two Masters degrees at Columbia University and did his postdoctoral training in cellular/molecular biology at NYU.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free